Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neurotoxicity of levodopa: treatment-associated homocysteine increase

Arising from: Weiner WJ (2006) Levodopa—toxic or neuroprotective? Nat Clin Pract Neurol 2: 518–519 doi:10.1038/ncpneuro0293

The excellent Viewpoint on the role of levodopa (LD) in the treatment of Parkinson's disease (PD) by William Weiner focuses on the saga of harmful LD, which arose from research in animals and cell cultures and from the clinical observation of motor complications in LD-treated patients with PD, related to the short half-life of the drug.1 It should also be mentioned that the long-term application of LD is associated with an increase in homocysteine levels. This increase might accelerate PD progression, promote peripheral neurodegeneration and induce neuropsychiatric symptoms and vascular disease, as indicated by experimental and clinical data.2,3,4 Elevated homocysteine levels can result in impaired endothelial function and a subsequent reduction in mitochondrial energy metabolism. This in turn induces the generation of oxidative stress, the release of nitric oxide—an excitotoxic compound that mediates neuronal degeneration—and dysfunction of the basal ganglia circuit. These processes resemble the pathophysiological changes in patients with PD.1,2 Therapeutic approaches for the LD-mediated neurotoxic homocysteine increase include vitamin (folic acid) supplementation and LD application in combination with a strong, centrally acting inhibitor of catechol-O-methyltransferase (COMT; an enzyme involved in the metabolism of LD), which prolongs the half-life and increases the brain delivery of LD.5,6

References

  1. 1

    Muller T (2002) Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 3: 1393–1403

    Article  Google Scholar 

  2. 2

    Lee ES et al. (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26: 361–371

    CAS  Article  Google Scholar 

  3. 3

    Nakaso K et al. (2003) Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207: 19–23

    CAS  Article  Google Scholar 

  4. 4

    Muller T et al. (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61: 657–660

    Article  Google Scholar 

  5. 5

    Postuma RB et al. (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66: 1941–1943

    CAS  Article  Google Scholar 

  6. 6

    Muller T and Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 62: 447–450

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Ralf Gold for his outstanding, stimulating contributions to the scientific discussion.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Thomas Müller.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Müller, T., Kuhn, W. Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat Rev Neurol 3, E1 (2007). https://doi.org/10.1038/ncpneuro0527

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing